Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
The aerospace-focused business, newly trading as a standalone entity under Honeywell’s umbrella, drew investor disappointment after its first earnings update since the separation moment came into focus.
THE APEX TIMES
THE APEX TIMES
Amazon Pharmacy is advertising steep discounts on weight-loss drug prescriptions for Medicare beneficiaries, intensifying competition with pharmacy chains and large retailers as demand grows for obesity and diabetes-linked therapies.
THE APEX TIMES
The carrier said it is making a billion-dollar push to improve service for its wireless customers as it has also raised prices this year.
THE APEX TIMES
Toyota says the reinvented 2027 C-HR remains in its battery-electric (BEV) form for a second model year, adding standard electronic all-wheel drive and citing 338 total system horsepower for the compact crossover.
THE APEX TIMES
The company said it has opened a new cloud region in India and expanded its data-center footprint, pushing deeper into a market where Amazon Web Services and Google Cloud are already heavily invested.
THE APEX TIMES
The company’s results were supported by stronger oil pricing and record production in the Permian Basin, underscoring how capital spending and operating execution in the basin continue to drive near-term earnings.
THE APEX TIMES
A new CVS Health Company Newsroom piece highlights wildfire smoke, extreme heat and Cyclospora as summertime risks, and points to how its retail pharmacists and health services can help people respond when conditions shift fast.
THE APEX TIMES
Moderna shares moved unevenly after the FDA approved the company’s mRNA-based flu vaccine, with traders weighing whether a regulatory win is enough to restart momentum.
THE APEX TIMES
A first-quarter insider-trading review cited by Yahoo Finance says Berkshire CEO Greg Abel reduced a portfolio of the company’s well-known equity holdings tied to Warren Buffett. The moves could reflect routine personal rebalancing, but they also raise the question of whether Abel is changing how the public equity side is approached.
